Centre for Neonatal Research and Education, School of Paediatrics and Child Health, University of Western Australia, Perth, WA, Australia.
Neonatal Clinical Care Unit, King Edward Memorial Hospital, Perth, WA, Australia.
Acta Paediatr. 2017 Nov;106(11):1747-1753. doi: 10.1111/apa.13826. Epub 2017 Apr 18.
To characterise the secreted and inducible antimicrobial protein and peptide (APP) levels in a prospective cohort of preterm infants (<30 weeks gestational age) with or without Bifidobacterium breve M16V supplementation during the first month of life.
We analysed serial biosamples of infants who did (n = 13) or did not receive (n = 62) B. breve (3 × 10 cfu/day). Peripheral blood was obtained on days 1, 14 and 28, and infant stool prior to commencement of probiotic supplementation and on day 21. Levels of APP (bactericidal/permeability inducing protein (BPI), beta defensins 1 and 2, lactoferrin, human cathelicidin, secretory phospholipase A2) in plasma and stool were determined. Further, we characterised induced APP levels in whole blood cultured with live S. epidermidis or with agonists of Toll-like receptors 2/6 and 4.
Stool, plasma and stimulated blood APP levels changed significantly during the first month of life. Supplementation with B. breve did not affect basal or stimulated APP levels except for a transient increase in inducible BPI.
Supplementation with B. breve does not appear to act via modulation of systemic or enteric APP expression in preterm infants although small effects cannot be excluded. Further work with other probiotic preparations is warranted.
在一项前瞻性队列研究中,分析有或没有补充短双歧杆菌 M16V 的早产儿(<30 周胎龄)在生命的第一个月中分泌型和诱导型抗菌蛋白和肽(APP)的水平。
我们分析了接受(n=13)或未接受(n=62)补充短双歧杆菌(3×10cfu/天)的婴儿的连续生物样本。在第 1、14 和 28 天采集外周血,在开始补充益生菌前和第 21 天采集婴儿粪便。测定血浆和粪便中 APP(杀菌/通透性增强蛋白(BPI)、β防御素 1 和 2、乳铁蛋白、人源杀菌肽、分泌型磷脂酶 A2)的水平。此外,我们还研究了用活表皮葡萄球菌或 Toll 样受体 2/6 和 4 激动剂培养全血诱导的 APP 水平。
粪便、血浆和刺激后的血液 APP 水平在生命的第一个月中发生显著变化。补充短双歧杆菌除了短暂增加诱导型 BPI 外,对基础或诱导型 APP 水平没有影响。
补充短双歧杆菌似乎不会通过调节早产儿的全身或肠道 APP 表达来发挥作用,但不能排除其产生较小影响的可能性。需要进一步研究其他益生菌制剂。